|
 The move would be the first arranged by the European Union executive
since it was mandated last week by the 27 EU national governments to
use an emergency fund with more than 2 billion euros ($2.3 billion)
available to reach advance purchase or call-option deals with up to
six vaccine makers.
The Commission's deal with the U.S. firm Johnson & Johnson is "in
the pipeline", a top health official from an EU member state said,
asking to remain anonymous as was mentioning confidential
discussions about vaccines between the EU executive and EU
governments.
A second EU source said the Commission had a call with Johnson &
Johnson on Tuesday over the possible agreement on its potential
vaccine.
A Commission spokesman had no comment. Johnson & Johnson was not
immediately available for comment outside U.S. business hours.
It was unclear whether any deal would involve an advance purchase of
the vaccine in testing, or an option to buy it.
Johnson & Johnson plans next month to start human clinical trials
for its experimental vaccine against the highly contagious
coronavirus, which has infected more than 8.36 million people
worldwide, with 447,985 deaths.
Germany, France, Italy and the Netherlands said last week they had
acquired 400 million potential vaccine doses, in principle available
to all member states, from British drugmaker AstraZeneca, which is
developing a COVID-19 shot in conjunction with Oxford University.
AstraZeneca signed a similar deal in May with the United States.
[to top of second column] |
DEAL AS SOON AS NEXT WEEK?
The health official from an EU state said the EU deal with Johnson & Johnson
could be announced as early as next week, but cautioned that it might take a
little longer to finalise, and there were still chances it might not be struck
at all.
EU decision-making procedures pose a sticking point for the potential deal, with
member states still in talks over the establishment of a steering board for
vaccine negotiations with drugmakers, officials told Reuters.
They said that under a draft plan devised by the EU Commission, which is still
to be approved by EU governments, a green light from just four member states
would be enough to start formal EU talks with a drugmaker.
But, underlining the urgency of securing a vaccine for the EU's 450 million
population, the Commission had already begun talks with Johnson & Johnson even
before the steering board has been agreed.
By buying vaccines under development, the EU risks acquiring shots that may
eventually prove unsuccessful against COVID-19.
But the risk is justified by the need to secure enough doses for the EU
population in the global race for an effective vaccine, EU officials say.
(Reporting by Elvira Pollina in Milan and Francesco Guarascio in Brussels;
Writing by Francesco Guarascio; Editing by Mark Heinrich)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
